Skip to main content
Equibles

ZYBT · Zhengye Biotechnology Holding Ltd · Metrics

Track ZYBT — free

Use ZYBT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZYBT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.46 +0.00 (+0.00%) At close · Oct 22
Rebalance outlook locked
Market Cap
$69.90M
Shares
47.39M
Volume · Oct 22 96.78K Avg daily vol (3M) 2.26M

ZYBT metrics

50 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.46
Market cap
$69.90M

Price action

20 metrics
Price change (1W)
-2.7%
Price change (30D)
+14.1%
Price change (3M)
-18.9%
Price change (6M)
+58.7%
Price change (YTD)
+27.0%
Price change (1Y)
-38.1%
Trailing year
Price change (5Y)
—
52-week high
$8.01
52-week low
$0.65
Change from 52-week high
-81.8%
Change from 52-week low
+126.0%
Annualized volatility
1,063.9%
Annualized volatility (3M)
222.7%
Beta
-0.7
RSI (14D)
51.5
Price vs SMA 50
-2.9%
Price vs SMA 200
+27.2%
Avg volume (3M)
2.26M
Relative volume
0.0
Average dollar volume
$4.65M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
47.39M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.0
reciprocal yield 51.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
20.5%
Operating margin
-60.6%
Trailing 12 months
Net margin
-60.0%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.27

Growth

11 metrics
Revenue growth YoY
-37.6%
Year over year
Net income growth YoY
-717.0%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-63.8%
Shares change YoY
+3.7%
Year over year · more shares
Revenue CAGR (3Y)
-23.5%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-27.9%
Return on assets
-16.0%
Debt / equity
—
Current ratio
1.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$7.20M
Total assets
$62.41M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
8
13F filer change QoQ
0
Institutional ownership
0.2%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-22.6%
Holder tenure
4.4
Price vs estimated holder cost
-87.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 5.6 days to cover
Days to cover
5.6d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1975641 CUSIP G989MS101 Visit website Investor relations